Company
Sareum Holdings PLC
LON:SAR
Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer. The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, including psoriasis, and has completed Phase 1 clinical development.
239 stories · page 1 of 12
Archive
Small Cap Feast
24 November 2022*A corporate client of Hybridan LLP** Arranged by most recent first*** Alphabetically arrangedDish of the dayJoiners:One Health Group plc (AQSE: OHGR), joins the Apex segment of the AQSE Growth Market.
Royal Mail not alone in benefiting from the pandemic
In the UK, the home delivery boom during the pandemic has clearly benefited many online operators while the fight against the coronavirus has thrown the spotlight on several biotechs
Archive
Ethernity Networks wins second sizeable 5G system contract
A look at the major movers on the London market on Friday
Archive
Grafton Group boosted by £520mln sale of merchanting business
A look at the major movers on the London stock market on Thursday
Archive
Shefa Gems to become tech cash shell
A look at some of the major movers in London on Tuesday
Proactive news headlines: Sareum, World High Life, Pelatro, Block Energy...
A glance at some of the day's highlights from the Proactive Investors newswire
Sareum hails government funding initiative for new COVID-19 treatments as a “welcome source of funding”
Sareum is currently carrying out preclinical research to assess the potential of its candidate, SDC-1801, in Covid
Sareum Holdings focused on clinical trial application
Dr Tim Mitchell, chief executive of Sareum, said he believes there is a "clear opportunity to generate significant value for our shareholders over the next 12 months"
Sareum receives worldwide rights to FLT3 programme
FLT3 is investigating kinase inhibitors, which are designed to reduce immune system overreaction to viral infections such as coronavirus (COVID-19)
Archive
Argo Blockchain the top riser after cash influx from options and warrants conversion
A look at some of the major movers in London on Thursday
Sareum Holdings formally receives US patent protection for its pre-clinical cancer programme
The drug developer’s chief scientific officer, Dr John Reader, said: "The granting of this patent in the US completes the protection of the intellectual property for our proprietary SDC-1802 Programme across all major markets."
Sareum highlights good progress despite challenging period due to coronavirus
Chairman Stephen Parker said the drug developer’s key focus remains on advancing the development of its two TYK2/JAK1 programmes, namely SDC-1801, targeting autoimmune diseases, and SDC-1802, targeting cancer
Archive
Proactive news headlines: Sareum, Location Sciences, Alien Metals, Remote Monitored System …
A glance at some of the day's highlights from the Proactive Investors newswire